Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of FMISO PET/MRI in Malignant Brain Tumors
NCT03649880Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2019
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluoromisonidazole in glioblastoma (GBM), sponsored by OHSU Knight Cancer Institute. Started Jun 2019; status: recruiting.
02
Drugs
fluoromisonidazole
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03649880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649880.